Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-04

Study Completion Date

2026-07-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The results of the present study will provide information on short-term safety and efficacy of a iPET and MTV-adapted therapeutic strategy, aimed to assess the feasibility and safety on immediate disease control of a standard ABVD chemotherapy without any further treatment in patients with a very low risk or treatment failure. A second very important endpoint will be the efficacy of INRT "on demand" followed by Nivolumab maintenance for one year to rescue patients failing first-line treatment and relapsing with the pattern of "limited relapse" in terms of 3-Y failure from 2 relapse (FF2R). Patients entering into the study will be also asked to participate to a long-term follow up study (beyond ten years) to assess the prevalence of late-onset cardiovascular effects and secondary tumors in the cohort of patients enrolled in the experimental and control arm of the study. An exploratory endpoint has been also added such as the role of Minimal Residual Disease (MRD) detection by cell-free DNA assay on peripheral blood samples obtained during treatment in predicting long-term disease control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

NCT01461928

Non-Hodgkin's Lymphoma

COMPLETED PHASE3

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

NCT05772624

Safety Issues Efficacy, Self

UNKNOWN PHASE2

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

NCT00141700

Lymphoma, Non-Hodgkin's

TERMINATED PHASE2

Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs

NCT05284396

Hodgkin Lymphoma

UNKNOWN

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959

Hodgkin's Lymphoma

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Nivolumab, total dose 5760 mg milligram

Group Type EXPERIMENTAL

Nivolumab 10 MG/ML

Intervention Type DRUG

Nivolumab, 100 mg, 10 mg/ml

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nivolumab 10 MG/ML

Nivolumab, 100 mg, 10 mg/ml

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged 18-60.
* Treatment-naïve, HL patients with Ann Arbor stage I or II A non-bulky disease stratified according to modified EORTC Criteria (refer to Appendix A);
* Patients must have histologically confirmed classical HL according to the current World Health Organization Classification (nodular sclerosis, mixed cellularity, lymphocytes rich, lymphocytes depleted, or classical HL NOS \[not otherwise specified\];
* ECOG performance status 0-2
* Hemoglobin must be \> 8 gr./dL
* Absolute neutrophil count ≥ 1,000/μL
* Platelet count ≥ 100,000/μL
* Voluntary written consent to take part to the study
* Serum Creatinine \< 2.0 mg/dL and/or Creatinine clearance or calculated Creatinine clearance \> 40 mL/minute
* Total bilirubin must be \< 2.0 x the upper limit of normal (ULN) unless known Gilbert syndrome
* ALT or AST must be \< 3 x the upper limit of normal.
* Female patients: if postmenopausal for at least 1 year before enrolment or, if fertile - agreeing to practice 2 effective methods of contraception or agreeing to practice true abstinence.
* Male patients should agree to practice barrier contraception or to practice abstinence

Exclusion Criteria

* Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma;
* Bulky disease (Lugano 2014 definition: single or conglomerated nodal mass with the largest diameter measuring 10 or more centimeters);
* B symptoms;
* Extra nodal site involved by disease;
* Female patients who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before first dose of study drug;
* Uncompensated diabetes mellitus requiring insulin therapy;
* Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol;
* Known human immunodeficiency virus (HIV) infection with a positive search for HIV antigens by immunoblot and/or circulating copies of HIV-RNA;
* Active hepatitis B with circulating copies of HBV-DNA, or active hepatitis C infection with circulating copies of HCV-RNA;
* Severely impaired, lung and renal function;
* Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection;
* Active autoimmune disorder in treatment with immunosuppressive drugs
* A left-ventricular ejection fraction \< 50%;
* Myocardial infarction within 2 years of study entry.
* Pregnancy or lactation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan M Zaucha, Professor, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of Gdansk

Andrea Gallamini, Professor, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Research and Clinical Innovation Department of the Lacassagne Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hematology Department IRCCS Policlinico San Matteo

Pavia, P.le Golgi 19, Italy

Site Status RECRUITING